New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you consider the use of ruxolitinib for tumor fevers and leukocytosis?

1 Answers

Mednet MemberInvited Expert
Allergy & Immunology · Medical University of South Carolina

No.

What are your top takeaways in Classical Hematology from ASH 2024?

9 Answers

Mednet MemberInvited Expert
Medical Oncology · Virginia Mason Medical Center

In the category of continuing what I already do, ASH 2024 provided an important confirmatory study of how to approach the treatment of patients with high-risk venous thromboembolism (VTE).In the EINSTEIN CHOICE (Rivaroxaban) and the AMPLIFY-EXT (Apixaban) studies, extended reduced-dose anti-coagulat...

What volume and dose would you use for a Stage I MALT lymphoma of the lung?

2 Answers

Mednet MemberInvited Expert
Radiation Oncology · University of Colorado School of Medicine

MALT lymphomas are highly radiosensitive. Curative standard doses are 24 Gy in 12 fractions and 30 Gy in 20 fractions. The latter and slower dose fractionation (30 Gy in 20) is best used specifically in the setting of stage IAE Gastric MALT - a unique site with significant risk of radiation induced ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

How do you manage newly diagnosed multiple myeloma patients who have a contraindication to steroids?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Loyola University Medical Center

This is a rather rare situation, but it can happen. Each patient will be different here. In my experience, this has been to psychosis/mania with previous steroid exposure.There is clear data that you can omit steroids following cycle 1 with daratumumab-based induction, cited here, but there are othe...

Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?

2
1 Answers

Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester

Excellent question! It is uncommon to start treatment for any malignancy without a pathologic proof and the age-old principle of 'Tissue is the Issue' applies to multiple myeloma as well. Having said that, certain emergent situations do merit starting treatment early without waiting for the biopsy o...

In patients with CML who are receiving 1st line TKI with good molecular response, are you continuing therapy or switching to asciminib based on the ASC4FIRST data?

2 Answers

Mednet Member
Hematology · Memorial Sloan Kettering Cancer Center

For a CML patient with optimal response and excellent tolerability to their current TKI, there should not be impetus to switch to asciminib. For patients with less than optimal response, diminished quality of life, and in certain settings of adverse effects from current therapy, consideration of TKI...

How do you decide the dose of aspirin to use in MPN patients?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · Massachusetts General Hospital

The standard dose for aspirin in the USA for MPN patients is aspirin 81 mg daily. I sometimes use 81 mg BID for patients with significant CV comorbidities. Some patients with headaches or microcirculatory symptoms may improve symptomatically with BID aspirin. Lastly, patients with erythromelalgia wi...

What volumes do you treat for ISRT for extranodal DLBCL?

1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

It is important to remember that ISRT, for both Hodgkin and non-Hodgkin lymphoma, consists of a set of principles that can be used to design rational radiation fields in the context of modern treatment planning. In general, only sites of original involvement are treated when patients also receive, a...

When utilizing ISRT for Hodgkin lymphoma, what volumetric expansions (ITV and PTV) are appropriate on top of the CTV that includes the original pre-systemic therapy disease?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center

First, it is important to realize that involved-site radiation therapy (ISRT) for Hodgkin lymphoma is not a formulaic approach to field design. It requires careful evaluation of pre-chemotherapy imaging, fusing these with post-chemotherapy planning CT scans for optimal target delineation, evaluating...

What is the appropriate RT dose for an advanced stage follicular lymphoma?

2
2 Answers

Mednet MemberInvited Expert
Radiation Oncology · Mayo Clinic Florida

Depends on the specific clinical scenario. However, in general, RT in advanced stage follicular lymphoma is palliative. Therefore, I would start 2Gyx2. Repeat as needed. If cord compression or something serious, would consider 24Gy.